Leerink Swann Cuts PT on Amicus Therapeutics (FOLD), But Remains Overall Bullilsh
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $14.49 --0%
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Leerink Swann cut its price target on Amicus Therapeutics (NASDAQ: FOLD) from $9 to $5 after the company reported Wednesday that Phase III study ('011) of Amigal monotherapy in Fabry disease missed its primary and secondary endpoints. However, they maintained an Outperform rating.
The firm notes, FOLD has two more shots on goal for Amigal monotherapy with 12-month data from study 011 in 1H13 and study 012 data in 2014.
"We also see other sources of value for the chaperone technology such as combination therapy with enzyme replacement therapy (ERT) where MEDACorp specialists are most interested, especially in other lysosomal storage disorders (LSDs) such as Pompe disease where the need is even greater, and AT 2220 is still unpartnered."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $5.77 yesterday.
The firm notes, FOLD has two more shots on goal for Amigal monotherapy with 12-month data from study 011 in 1H13 and study 012 data in 2014.
"We also see other sources of value for the chaperone technology such as combination therapy with enzyme replacement therapy (ERT) where MEDACorp specialists are most interested, especially in other lysosomal storage disorders (LSDs) such as Pompe disease where the need is even greater, and AT 2220 is still unpartnered."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $5.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
- Cummins (CMI) PT Lowered to $675 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
